Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ApexOnco Front Page
Recent articles
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Artios, Synnovation and Novartis show mere glimmers of activity.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
The company reveals the first overall survival data in adjuvant ER-positive breast cancer.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.
